The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives
- PMID: 18932238
- DOI: 10.1002/ajh.21291
The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives
Abstract
The Philadelphia (Ph) chromosome is characteristic of chronic myelogenous leukemia (CML), but it is also the most frequent cytogenetic abnormality in precursor B-lymphoblastic leukemia (ALL) of adults. The vast majority of CML patients have a BCR-ABL translocation that yields a 210 kD (p210) oncoprotein, whereas adult Ph-positive ALL cases can present with either a p190 or a p210 oncoprotein, or both. Considering that 30% of the patients with CML that progress to blast crisis will have a lymphoblastic presentation, adults presenting with a p210 ALL may have either a de novo ALL or CML presenting for the first time in lymphoblastic phase. To identify the distinguishing features, cases of p190-ALL, p210-ALL, and lymphoblastic CML were compared. In spite of significant overlap between the three entities, a number of features were found to aid in their differentiation. p210-ALL patients present at a younger age with blasts that frequently show loss of expression of CD34, whereas p190-ALL patients present with marked increase in peripheral blast percentage. Interestingly, bone marrow findings characteristic of a myeloproliferative disorder are specific, but are not sensitive for lymphoblastic CML. This study suggests that despite the similarities between these leukemias, p190-ALL, p210-ALL, and lymphoblastic phase CML likely represent three distinct diseases.
Copyright 2008 Wiley-Liss, Inc.
Similar articles
-
Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.Leukemia. 1996 May;10(5):795-802. Leukemia. 1996. PMID: 8656674
-
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.Blood. 1996 Jun 15;87(12):5213-7. Blood. 1996. PMID: 8652835
-
Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.Biol Blood Marrow Transplant. 1997 Oct;3(4):179-86. Biol Blood Marrow Transplant. 1997. PMID: 9360779
-
[Cytogenetic and clinical features of Philadelphia chromosome positive leukemias].Verh Dtsch Ges Pathol. 1990;74:36-42. Verh Dtsch Ges Pathol. 1990. PMID: 1708614 Review. German.
-
Molecular insights into the Philadelphia translocation.Hematol Pathol. 1991;5(1):1-10. Hematol Pathol. 1991. PMID: 2050600 Review.
Cited by
-
Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era.Exp Hematol Oncol. 2022 Mar 11;11(1):13. doi: 10.1186/s40164-022-00265-2. Exp Hematol Oncol. 2022. PMID: 35277197 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous